We exploit dislocations in markets and unlock value from complex situations using a Get Rich and Stay Rich strategy. This strategy has given rise to returns over 23 years of 28% p.a. Net IRR
Brooklyn ImmunoTherapeutics’ Board of Directors announce new Senior Management hires
Brooklyn ImmunoTherapeutics, a clinical-stage company developing novel immunotherapies focused on reducing immune suppression seen in the cancer tumour micro-environment, has announced two major hires in the senior management team.
Mark Leuchtenberger has been appointed as President, Chief Executive Officer and Director, while Monil Shah takes the position of Chief Operating Officer. One of the first tasks of the new President, CEO and Director was to present at the BioCentury 24th Annual Future Leaders in the Biotech Industry Conference in New York City on April 7th, 2017. Previous CEO and founder of IRX John W. Hadden II will continue as Director.
Mr. Leuchtenberger brings 20 years of experience as a senior executive in the biopharmaceutical industry where he has led companied through private financings and initial public offerings, taken products from IND through to commercialization and achieved M&A exits. He has served as President and Chief Executive Officer of companies such as Chiasma, Acusphere, Inc., and Rib-X Pharmaceuticals, Inc. (now Melinta Therapeutics Inc.). Mr. Leuchtenberger served as President and Chief Executive Officer of Targanta Therapeutics Corporation, where he led the company’s initial public offering in 2007 and its acquisition by The Medicines Company in 2009. Mr. Leuchtenberger served as the President and Chief Executive Officer of cancer vaccine company, Therion Biologics Corporation.
Dr. Shah brings a similar wealth of experience through 17 years of pharmaceutical and biotechnology industry experience in Oncology drug development, including Clinical Research and Development and Medical Affairs. Most recently, Dr. Shah was the Medical Affairs Lead for Immuno-Oncology at Bristol Myers Squibb. Dr. Shah helped start a biotech company as the Head of Clinical Operations and Development at Ventrus Biosciences. Prior to Ventrus, Dr. Shah led the solid tumour development programs and was eventually offered the opportunity to lead the clinical portfolio and strategic planning function at Celgene Corporation.
For more information on Brooklyn ImmunoTherapeutics, see https://www.brooklynitx.com/
02/09/2024
A £175 million communications network connecting 163 remote radio sites across 11,000 miles of UK coastline is now operational ensuring His Majesty’s (HM) Coastguard’s effective frontline emergency response continues for thousands of distress calls from the UK’s waters.
12/06/2024
LS EcoEnergy (CEO Lee Sang-ho) announced on the 12th that the company has entered into negotiations to secure the land for a submarine cable project in the UK.
LS EcoEnergy is actively engaged in negotiations toleaseland atthe Port of Tyne in the northeast. The size of the project site, including the port, is approximately154,711㎡.LS EcoEnergy plans to conclude negotiations ‒ including land lease conditions ‒ within the year.
Click the link in the title to read full article.
12/06/2024
More than 30,000 students and staff at the University of Bristol will soon have access to a new and improved Wi-Fi experience thanks to a major new wireless network project that will be delivered by Telent. It will be one of the largest education networks outside of North America, with the capacity to support over 300,000 devices.
Click the link in the title to read more
04/06/2024
As part of Telent’s Environment and Sustainability vision, Telent’s dedicated Green Solutions team have been exploring and developing a range of innovative Green Solutions to benefit the environment, customers and it’s supply chain to improve sustainability and reduce its carbon footprint.
Click the link in the title to read more
29/05/2024
PIC, a specialist insurer of defined benefit pension schemes, has concluded a £204 million full buy-in of the Arqiva Defined Benefit Pension Plan (“the Plan”). The transaction secures the pensions of both deferred and pensioner members of the Plan, which is sponsored by Arqiva Limited (“the Company”), a British telecommunications company, comprising 589 current pensioners and dependents and 215 deferred members.
Click the link in the title to read more
27/05/2024
Multiple updates announced from Global Interconnection Group Limited, including:
Global InterConnection Group negotiations to build HVDC cable factory at Port of Tyne
In Joint Venture with one of the subsidiaries of LS Group, Korea
Global InterConnection Group to appoint new CEO
Click the link in the title to read more